
A path forward for accuracy, consistency, and public confidence
I. Introduction: Why reform is needed—and how Clinical Validation can help
Medicare Advantage (MA) risk adjustment has become an area of sustained attention from policymakers, lawmakers, regulators, researchers, and the public. This scrutiny reflects the MA program’s growth, and risk adjustment’s fiscal importance, and complexity. As MA enrollment now accounts for more than half of all Medicare beneficiaries, even modest imperfections in risk adjustment design can have outsized consequences for federal spending, beneficiary trust, and public confidence in the program.
Risk adjustment plays a critical role in ensuring that MA plans are fairly compensated for enrolling beneficiaries with greater clinical needs. At the same time, policymakers have raised bipartisan concerns about whether the current framework sufficiently promotes accuracy, consistency, and comparability across plans and providers. Addressing these concerns is essential to sustaining Medicare Advantage as a stable and credible component of Medicare.
This paper makes the case for targeted reforms to the diagnostic coding and risk adjustment framework to improve clarity, consistency, and alignment with medical professional societies, a collective framework we call Clinical Validation. This paper recognizes that structural features of the current diagnostic coding and risk adjustment framework create ambiguity and variability, even when all parties act in good faith and in compliance with existing rules. Reform is therefore warranted—not as a punitive measure, but as an alignment to clinical standards.
Clinical Validation offers a promising technical-based solution. Properly designed, it can reduce unnecessary variation, strengthen confidence in reported diagnoses, protect provider clinical judgment, and preserve the intent of risk adjustment while preventing the gamification that risks destabilizing the program. Clinical Validation represents a reform path around which CMS, Congress, stakeholders, and the public can align.
II. Background: How risk adjustment relies on diagnostic coding today
A. Provider diagnosis as the foundation
Under current Medicare rules, diagnosis codes used for risk adjustment originate with treating clinicians and are reported consistent with the ICD‑10‑CM Official Guidelines for Coding and Reporting. Those guidelines make clear that:
- Diagnosis assignment is based on the provider’s documented clinical judgment.
- Coders and reviewers are not instructed to apply independent clinical criteria when assigning diagnosis codes.
- Discrepancies in documentation are addressed through clarification—not substitution of judgment.
This framework appropriately protects provider diagnostic authority and supports efficient clinical documentation. It also reflects Medicare’s historical reliance on claims‑based data systems. However, the interplay of ICD-10 diagnostic frameworks with MA risk adjustment structures underscore the different purposes for these systems and their overall incompatibility with the fee-for-service claims architecture of traditional Medicare.
B. A structural challenge in a prospective payment model
While ICD‑10 coding rules were developed for claims processing and retrospective payment, Medicare Advantage risk adjustment operates differently. MA uses reported diagnoses prospectively to estimate future costs and set capitated payments.
This difference matters. In a prospective payment model:
- Small differences in diagnosis prevalence can materially affect payments.
- Coding variation—whether clinical, methodological, or interpretive—can accumulate over time.
- CMS must rely on downstream data integrity rather than real‑time clinical adjudication.
The system therefore depends heavily on consistent interpretation of what constitutes a “valid” diagnosis for payment purposes, even though ICD‑10 itself intentionally refrains from defining clinical diagnostic thresholds.
III. The gap: Absence of a uniform Clinical Validation standard
A. What Clinical Validation is – and is not
CMS has long distinguished Clinical Validation from coding accuracy. Clinical Validation refers to a review of the medical record to assess whether documented diagnoses are supported by clinical evidence. Importantly:
- Clinical Validation does not evaluate the competence or intent of the treating provider.
- It does not replace provider judgment.
- It asks whether the record contains sufficient clinical indicators to support that judgment for a specific diagnosis.
Outside of Medicare Advantage, clinical validation is routinely used in hospital auditing, quality reporting, and utilization review – but typically under clearly defined criteria.
B. The problem: No national standard for MA risk adjustment
In Medicare Advantage, there is no nationally recognized, diagnosis‑specific clinical validation standard for conditions included in the CMS‑HCC risk adjustment model. As a result:
- Different reviewers may reach different conclusions based on the same documentation.
- Stakeholders may rely on implicit or internally developed thresholds.
- Risk score optimization creates potential for misuse and abuse rather than focusing on underlying clinical importance.
To manage this uncertainty, CMS has taken important steps, most notably through model revisions such as CMS‑HCC Version 28, which removes diagnosis categories deemed especially susceptible to coding variation. While appropriate, this approach treats symptoms rather than causes. It reduces sensitivity to discretion but does not resolve the underlying absence of shared diagnostic benchmarks.
In the current practice, code assignment relies on provider documentation that the condition exists rather than the specific clinical criteria used to establish it. This situation creates opportunity for violations of Principle 10 wherein prevalence rates of diagnoses in fee for service differ from those in coordinated care plans. For example, a provider may document malnutrition based on a patient’s prealbumin level instead of American Society for Parenteral and Enteral Nutrition (ASPEN) criteria, and the diagnosis can still be coded in alignment with the ICD-10-CM Official Guidelines for Coding and Reporting, which emphasize the primacy of provider documentation.[1] The malnutrition codes were eliminated from risk adjustable payment in V28.
[1] Karen Marini Carr et al., Clinical Validation Practice Brief (2023 Update) (Chicago: AHIMA, 2023), 6
IV. Why standardized Clinical Validation is a better policy tool
A. Aligning risk adjustment with evidence‑based medicine
For many risk‑adjusted conditions, professional medical societies already maintain evidence‑based diagnostic guidelines. These guidelines:
- Are developed through transparent, consensus‑driven processes.
- Reflect current clinical evidence.
- Are routinely updated.
Yet, CMS does not currently require alignment between risk‑adjusted diagnoses and these established diagnostic frameworks. Clinical Validation would not mandate rigid criteria at the point of care; instead, it would clarify what clinical evidence is sufficient to substantiate a diagnosis for risk adjustment purposes.
B. Reducing variation without undermining care delivery
If implemented carefully, Clinical Validation can:
- Preserve clinician autonomy in diagnosing and treating patients.
- Reduce unnecessary retrospective disputes over documentation.
- Improve comparability across plans and regions.
- Support more accurate population‑level data on disease burden.
Crucially, this approach improves program integrity without assigning fault or presuming improper behavior by any participant.
V. A policy framework for Clinical Validation reform
This paper proposes a targeted, feasible framework that equips CMS with the authority to implement and restore program integrity through the establishment of a clinical criteria model. This new framework removes systematic abuses and builds on the relevance of patient care rather than retrospective payment incentives.
A. Establish diagnosis‑specific Clinical Validation criteria for MA risk adjustment
Congress should enact legislation that directs CMS to establish standardized clinical validation criteria for selected diagnoses used in Medicare Advantage risk adjustment. These criteria would:
- Apply only for payment validation, not for clinical practice regulation.
- Identify commonly accepted clinical indicators (e.g., history, examination findings, diagnostics, treatment).
- Be diagnosis‑specific and evidence‑based.
- Be transparent and publicly available.
B. Leverage professional medical societies as clinical stewards
Rather than CMS independently defining medical criteria, Congress could authorize CMS to recognize professional medical societies as clinical stewards for diagnostic validation standards relevant to their specialties. Societies already perform this role in:
- Clinical guideline development,
- Quality measure endorsement,
- Coverage and treatment pathway recommendations.
This approach ensures clinical credibility while minimizing administrative burden.
C. Phase‑in through targeted application
To avoid disruption, CMS could:
- Begin with a limited subset of high‑impact or historically variable conditions.
- Pilot validation standards before full implementation.
- Align timing with model updates and audit cycles.
A phased approach allows refinement and stakeholder feedback while creating early wins for accuracy and confidence.
VI. Benefits for policymakers, CMS, and the public
Standardized clinical validation offers distinct advantages over alternative reform strategies:
- Improved accuracy: Payments better reflect documented clinical reality.
- Reduced controversy: Clear standards shift debate from intent to evidence.
- Provider protection: Clinicians gain clarity about documentation expectations without second‑guessing.
- Administrative predictability: Plans and CMS operate under shared rules rather than post hoc interpretation.
- Public confidence: Transparency strengthens trust in MA risk adjustment.
Importantly, this reform complements—not replaces—existing coding standards and CMS oversight tools.
VII. Conclusion: A constructive path forward
Medicare Advantage risk adjustment does not suffer from a lack of rules; it suffers from rules designed for a different payment era. As the program continues to mature, policymakers have the opportunity to modernize it in a way that is fair, evidence‑based, and broadly acceptable.
Clinical Validation is not about accusing stakeholders or rewriting clinical practice. It is about clarifying expectations, aligning payment with evidence, and reinforcing the integrity of a program relied upon by millions of beneficiaries.
With thoughtful design and phased implementation, clinical validation can move Medicare Advantage risk adjustment beyond controversy—toward clarity, consistency, and shared accountability.
Authors
Eric Cahow, PhD, MBA
Rackelle Wilkinson-Alston, MSN, RN, CRC, CDIP
Tina M. Moreland, MPH, RN, CPC, CRC


